nach oben

Intensive Care Medicine

Erschienen in:

15.10.2020 | Less is more in Intensive Care

Biomarkers in the ICU: less is more? No

verfasst von: Antoni Torres, Antoni Artigas, Ricard Ferrer

Erschienen in: Intensive Care Medicine | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

In recent years, the use of biomarkers in the ICU has increased exponentially. Only a few of them are used in clinical practice. However, as any measurement that helps to make clinical decisions, these biomarkers have detractors and defenders. Due to space constrictions, we decided to give arguments in favor of using biomarkers only in two frequent medical conditions with high morbidity and mortality in ICU, such as pneumonia and sepsis. …

Méndez R, Menéndez R, Cillóniz C, Amara-Elori I, Amaro R, González P et al (2018) Initial Inflammatory profile in community-acquired pneumonia depends on time since onset of symptoms. Am J Respir Crit Care Med 198(3):370–378CrossRef

Torres A, Chalmers JD, Dela Cruz CS, Dominedò C, Kollef M, Martin-Loeches I et al (2019) Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med 45(2):159–171CrossRef

Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR et al (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174(1):84–93CrossRef

Scheutz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M et al (2018) Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis 18:95–107CrossRef

De Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE et al (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16(7):819–827CrossRef

Torres AA, Sibila O, Ferrer M, Polverino E, Menéndez R, Mensa J et al (2015) Effect of Corticosteroids on treatment failure among hospitalized patients with sever community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313(7):677–686CrossRef

Torres A, Niederman MS, Chastre J, Ewig S, Fernández-Vandellos P, Hanberger H et al (2017) International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J 50(3):1700582CrossRef

Póvoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P et al (2005) C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study. Eur Respir J 25(5):804–812CrossRef

Póvoa P, Martin-Loeches I, Ramirez P, Bos LD, Esperatti M, Silvestre J, Gili G, Goma G, Berlanga E, Espasa M, Gonçalves E, Torres A, Artigas A (2016) Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study. Ann Intensive Care 6(1):32CrossRef

10.

Van Oort PM, Bos LD, Póvoa P, Ramirez P, Torres A, Artigas A et al (2019) Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia. ERJ Open Res 5(1):00212–2018PubMedPubMedCentral

11.

Wacker C, Prkno A, Brunkhorst FM, Schlattmann P (2013) Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 13(5):426–435CrossRef

12.

Kim SJ, Hwang SO, Kim YW, Lee JH, Cha KC (2019) Procalcitonin as a diagnostic marker for sepsis/septic shock in the emergency department; a study based on Sepsis-3 definition. Am J Emerg Med 37(2):272–276CrossRef

13.

Briassoulis G, Briassoulis P, Miliaraki M, Ilia S, Parlato M, Philippart F et al (2019) Biomarker cruises in sepsis: who is the CAPTAIN? Discussion on “Circulating biomarkers may be unable to detect infection at the early phase of sepsis in ICU patients: the CAPTAIN prospective multicenter cohort study”. Intensive Care Med 45(1):132–133CrossRef

14.

Gibot S, Bene MC, Noel R, Massin F, Guy J, Cravoisy A et al (2012) Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 186(1):65–71CrossRef

15.

Schuetz P, Beishuizen A, Broyles M, Ferrer R, Gavazzi G, Gluck EH et al (2019) Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med 57(9):1308–1318CrossRef

16.

Baldira J, Ruiz-Rodriguez JC, Wilson DC, Ruiz-Sanmartin A, Cortes A, Chiscano L et al (2020) Biomarkers and clinical scores to aid the identification of disease severity and intensive care requirement following activation of an in-hospital sepsis code. Ann Intensive Care 10(1):7CrossRef

Titel: Biomarkers in the ICU: less is more? No
verfasst von: Antoni Torres
Antoni Artigas
Ricard Ferrer
Publikationsdatum: 15.10.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Intensive Care Medicine / Ausgabe 1/2021
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-020-06271-4

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Biomarkers in the ICU: less is more? No

Excerpt

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

COVID-19: what the clinician should know about post-mortem findings